Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Duncan Richards

Today, we formally welcome Professor Duncan Richards as the new Director to OCTRU, replacing Professor Sarah (Sallie) Lamb who, together with Professor Doug Altman founded the CTU back in 2012. 

Professor Richards, an Oxford-trained clinician, joins OCTRU from his previous roles as Head of Clinical Pharmacology and Experimental Medicine at GSK, and Research Director of GSK’s phase 1 and experimental medicine unit in Cambridge (CUC).

Professor Lamb is moving to a new role at Exeter University, but will continue as Strategic Lead for OCTRU’s Rehabilitation Research group. 

Members of the unit are looking forward to the continued evolution of OCTRU under Professor Richards, building on its reputation as a firmly established CTU conducting numerous clinical trials across all phases and areas of medicine. Professor Richards said: ‘In my short time in Oxford I have been tremendously impressed by the breadth and quality of work undertaken by OCTRU and its partners. I would like to pay tribute Sallie and the team for building a robust but flexible organisation that is ready to take on new challenges and opportunities as the clinical trials portfolio continues to evolve.’

Similar stories

WHiTE Four trial results!


The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!


The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

ARCADIAN trial opens to recruitment!


The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand


Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

HUSH trial opens to recruitment!


The HUSH trial has received OCTRU Green Light approval and is now open to recruitment!

Oxford researchers start new trial on the use of anti-TNF to treat Covid-19 in care homes

Main OCTRU Trials

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.